New Zealand markets open in 5 hours 22 minutes

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3600+0.0200 (+0.60%)
At close: 04:00PM EDT
3.2500 -0.11 (-3.27%)
After hours: 05:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.3400
Open3.3800
Bid3.3400 x 300
Ask3.3700 x 200
Day's range3.2300 - 3.6200
52-week range1.6000 - 4.2700
Volume548,297
Avg. volume522,843
Market cap325.778M
Beta (5Y monthly)0.53
PE ratio (TTM)N/A
EPS (TTM)-1.1700
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 7:55am PT | 10:55am ET.

  • PR Newswire

    Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Monday, June 17, 2024 at 1:00 p.m. PT.

  • PR Newswire

    Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2024.